Phaseline

Targets › MIR126

MIR126: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2028.

Open in Phaseline: the race on MIR126, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CentermiRisten
miR-126 inhibitor; CpG-linked anti-miR-126 oligonucleotide
MIR126Phase 1Recurrent Acute Myeloid LeukemiaMar 2028

Conditions

Recurrent Acute Myeloid Leukemia (1)

Modalities

other (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.